Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
公司代碼GCTK
公司名稱GlucoTrack Inc
上市日期Apr 09, 2013
CEOGoode (Paul V)
員工數量11
證券類型Ordinary Share
年結日Apr 09
公司地址301 Rt 17 North
城市RUTHERFORD
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編07070
電話197286757878
網址https://glucotrack.com/
公司代碼GCTK
上市日期Apr 09, 2013
CEOGoode (Paul V)